Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27516715 | 0.82 | KCNH2 (0.52) | KCNH2LMNAL3MBTL1CYP2D6TSHR | |
| SCHEMBL5415267 | 0.80 | KCNH2 (0.50) | KCNH2LMNAL3MBTL1CYP2D6TSHR | |
| SCHEMBL27541351 | 0.80 | KCNH2 (0.50) | KCNH2F2HSP90AA1HSP90B1LMNA | |
| SCHEMBL15929449 | 0.80 | ALDH1A1 (0.51) | KCNH2HSP90AA1HSP90B1LMNATSHR | |
| SCHEMBL28245281 | 0.80 | KCNH2 (0.55) | KCNH2LMNAL3MBTL1CYP2D6TSHR | |
| SCHEMBL2950629 | 0.74 | LMNA (0.71) | KCNH2LMNAL3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL27541363 | 0.74 | LMNA (0.50) | KCNH2LMNAL3MBTL1CYP2D6TSHR | |
| SCHEMBL4857301 | 0.73 | PDE4B (0.55) | KCNH2LMNAKDM4C | |
| SCHEMBL4858800 | 0.73 | MEN1 (0.60) | — | |
| SCHEMBL27517353 | 0.73 | LMNA (0.53) | KCNH2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | KCNH2 2535/4885F2 3937/4885HSP90AA1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.